News

  • Nafamostat for treatment of COVID-19

    by Doherty Media
    As COVID-19 is a new disease resulting in an unprecedented global healthcare burden, there have been a very large number of drugs rapidly escalated...

  • AustralaSian COVID-19 Trial opens in India

    by Doherty Media
    The AustralaSian COVID-19 Trial (ASCOT) has been expanded into India, with the first patients recruited last week to the first two sites, Christi...

  • ASCOT removes convalescent plasma from trial

    by Doherty Media
    The ASCOT International Trial Steering Committee (ITSC) has made the decision to cease enrolment into the convalescent plasma arm of the trial. A ...

  • The case for including pregnant women in COVID-19 clinical trials

    by Doherty Media
    Written by Dr Megan Rees, Chief Investigator, AustralaSian COVID-19 Clinical Trial, Respiratory and Sleep Physician, Royal Melbourne Hospital on b...

  • Standard of care explained

    by Doherty Media
    Written by Dr Megan Rees, Chief Investigator, AustralaSian COVID-19 Clinical Trial, Respiratory and Sleep Physician, Royal Melbourne Hospital and ...

  • It is scary enough being treated for COVID-19 – why would a patient also consider being part of a research trial?

    by ASCOT Trial
    Written by Dr Megan Rees, Chief Investigator, AustralaSian COVID-19 Clinical Trial, Respiratory and Sleep Physician, Royal Melbourne Hospital and ...

  • Convalescent plasma for COVID-19

    by ASCOT Trial
    Convalescent plasma is a treatment arm in ASCOT. Participants are randomised (like the flip of a coin) to either receiving convalescent plasma or the usual best standard of care without convalescent plasma.

  • AustralaSian COVID-19 Trial (ASCOT) removes hydroxychloroquine and lopinavir/ritonavir arms of the trial

    by ASCOT Trial
    Following reports that that hydroxychloroquine and lopinavir/ritonavir are not effective in reducing mortality from COVID-19, the AustralaSian COVID-19 Trial (ASCOT) Steering Committee has also made the decision to remove the hydroxychloroquine and lopinavir/ritonavir arms of the Trial.

  • Convalescent plasma treatment for COVID-19 introduced to ASCOT and REMAP-CAP trials

    by ASCOT Trial

    Convalescent plasma has been introduced to the AustralaSian COVID-19 Trial (ASCOT) and Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) clinical trials in a bid to identify the best strategy to treat patients hospitalised with COVID-19. 

  • A COVID-19 Effect on Scientific Research

    by ASCOT Trial
    The world, as we alive now know it, is in uncharted territory. COVID-19 has spread inexorably to every part of our planet. Governments, leaders, and health care policy professionals are engaging with health care providers, business and social experts to curb the march of fatality and disease. Economic and broader threats to communities are emerging daily. To face down this menace, all have responded with unparalleled speed.

  • Macquarie Group Foundation commits $1 million to the AustralaSian COVID-19 Trial

    by ASCOT Trial
    The AustralaSian COVID-19 Trial (ASCOT) has received a significant funding commitment of $1 million from the Macquarie Group Foundation.

  • A Consumer Representative's experience working on a COVID-19 clinical trial

    by ASCOT Trial
    Sue Anderson is the Consumer Representative on the AustralaSian COVID-19 Clinical Trial (ASCOT) Steering Committee. She writes here of her experience.